Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

PHASE1TerminatedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

November 19, 2019

Primary Completion Date

November 28, 2023

Study Completion Date

November 28, 2023

Conditions
Gastrointestinal TumorsColorectal AdenocarcinomasGastric AdenocarcinomasEsophageal Adenocarcinomas
Interventions
DRUG

PF-07062119

PF-07062119

DRUG

Anti-PD1

Anti-PD1 PF-06801591

DRUG

Anti-VEGF

Anti-VEGF IV (bevacizumab)

Trial Locations (19)

3000

Peter MacCallum Cancer Centre, Melbourne

3050

The Royal Melbourne Hospital, Parkville

10022

Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavillion, New York

10065

Evelyn H. Lauder Breast and Imaging Center, New York

Memorial Sloan Kettering Cancer Center - Main Campus, New York

44106

University Hospitals Cleveland Medical Center, Cleveland

49546

START Midwest, Grand Rapids

77030

University of Texas MD Anderson Cancer Center, Houston

78229

Christus Santa Rosa Hospital, San Antonio

NEXT Oncology, San Antonio

80045

University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora

University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP), Aurora

University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP), Aurora

90055

UCLA Department of Medicine: Hematology-Oncology, Los Angeles

90404

UCLA Hematology Oncology - Santa Monica, Santa Monica

91010

City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte

City of Hope IDS Pharmacy, Duarte

277-8577

National Cancer Center Hospital East, Kashiwa

104-0045

National Cancer Center Hospital, Chuo-ku

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04171141 - Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. | Biotech Hunter | Biotech Hunter